Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders will be held Wednesday, May 6, 2026 at 12:00 p.m. Eastern Time. The meeting will be conducted virtually via the internet and the live webcast will include audio and the slide presentation.
A recording will be available beginning 10:30 a.m. ET on Thursday, May 7, 2026 at www.virtualshareholdermeeting.com/SYK2026 and will remain available until the company files its definitive proxy statement for the 2027 annual meeting.
GE HealthCare (Nasdaq: GEHC) appointed Kevin A. Lobo, Chair and CEO of Stryker (NYSE: SYK), to its Board of Directors effective March 13, 2026.
Mr. Lobo brings more than 25 years of medtech, operational and financial leadership, including service as Stryker CEO since October 2012 and Stryker board chair since July 2014, and experience at Johnson & Johnson, KPMG, Unilever and Kraft Canada.
Stryker (NYSE:SYK) launched the SmartHospital Platform on March 9, 2026, a digital foundation to connect devices, data and care teams into one adaptive hospital ecosystem.
Key features include connected infrastructure, clinical communication (Sync Badge), the Engage workflow engine, virtual care and ambient intelligence to streamline operations and support bedside staff.
Stryker (NYSE: SYK) highlighted new orthopaedic product advances at the AAOS 2026 Annual Meeting on March 3, 2026, including Triathlon Gold (titanium nitride femoral component), a Triathlon Medial Stabilized insert, full market release of Mako Shoulder, Mako RPS handheld robotics, and new power tools BPX and TPX HD.
Attendees can view demos and symposiums at booth #3339.
Stryker (NYSE:SYK) launched Synchfix EVT, a next‑generation flexible syndesmotic fixation device designed to simplify surgical deployment and support ankle stabilization for adults and adolescents. The all‑in‑one system integrates suture tensioning handles, enables one‑handed implant deployment, and uses a low‑profile titanium medial implant. Synchfix EVT is the first flexible ankle syndesmotic fixation device indicated for adolescents and earned a Red Dot Design Award. Stryker is showcasing the sterile, single‑use, knotless, flexible suture‑button system at the 2026 ACFAS Annual Meeting with demonstrations highlighting procedural efficiency.
Stryker (NYSE: SYK) launched the T2 Alpha Humerus Nailing System on February 11, 2026, adding to its T2 Alpha portfolio.
The system uses SOMA-informed design from CT data to improve anatomical fit, offers up to 6mm active intraoperative compression, multiplanar locking screws, and guided targeting to streamline humerus fracture fixation and OR workflow.
Stryker (NYSE: SYK) announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, introducing Mako Handheld Robotics as an expansion of the Mako family. Mako RPS integrates an intraoperative planner and a robotically enabled saw compatible with Triathlon Total Knee and Q Guidance System.
The system offers active adjustment technology that guides a surgeon's saw to align with the surgical plan and aims to fit into existing workflows without cutting blocks. Stryker will demonstrate Mako SmartRobotics and Mako Handheld Robotics at AAOS 2026, booth #3339.
Stryker (NYSE:SYK) declared a quarterly cash dividend of $0.88 per share, payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026.
The dividend equals the prior quarter and represents a 4.8% increase year-over-year, reflecting steady shareholder distributions.
Stryker (NYSE:SYK) reported strong fourth-quarter and full-year 2025 operating results: Q4 net sales $7.17B (+11.4%), full-year net sales $25.12B (+11.2%), organic growth Q4 +11.0% and FY +10.3%. Adjusted operating margin expanded +100 bps to 30.2% (Q4) and 26.3% (FY). 2026 outlook: organic sales growth of 8.0%–9.5% and adjusted EPS of $14.90–$15.10.
Cash flow from operations was $5.04B; acquisitions spending was $4.96B in 2025. Management cites strong capital-product demand and procedural volumes entering 2026.
VB Spine completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France on January 6, 2026, expanding its global manufacturing footprint.
The Cestas site, including its people, infrastructure, and processes, will anchor VB Spine's worldwide manufacturing strategy and support expanded medical education and training programs in Europe. Employees transitioned from Stryker to VB Spine and manufacturing operations continue without interruption. Integration planning is underway to align systems, quality, and supply chain.